Patients Can't Wait: Building Regional Manufacturing for Global Advanced Therapy Access

Today, most cell and gene therapies are manufactured in a small number of locations in the US and Europe, creating global supply bottlenecks that delay patient access and increase costs. Across the world, new regions are investing in localized manufacturing capacity to build more resilient supply chains and bring advanced therapies closer to patients. This session explores how emerging biotech ecosystems'including those in the Middle East'are building advanced therapy manufacturing capabilities through strategic partnerships, technology transfer, and public'private collaboration. The real impact of global supply dependency on patient access in MENA How localisation can reduce time-to-treatment and improve outcomes The role of public-private partnerships in accelerating access Why MENA has a unique opportunity to lead in region-specific gene therapies